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Inhibition of Glycogen Synthase Kinase-3 Increases
the Cytotoxicity of Enzastaurin
Mark A. Rovedo1, Nancy L. Krett1 and Steven T. Rosen1,2
Cutaneous T-cell lymphomas (CTCL) represent a spectrum of several distinct non-Hodgkin’s lymphomas that
are characterized by an invasion of the skin by malignant, clonal lymphocytes. Our laboratory has previously
demonstrated that the protein kinase C (PKC) b inhibitor Enzastaurin increases apoptosis in malignant
lymphocytes of CTCL. These results directly led to a clinical trial for Enzastaurin in CTCL in which it was well
tolerated and showed modest activity. To ascertain a means of improving the efficacy of Enzastaurin, we
investigated complementary signaling pathways and identified glycogen synthase kinase-3 (GSK3) as important
in survival signaling in CTCL. Enzastaurin combined with GSK3 inhibitors demonstrated an enhancement of
cytotoxicity. Treatment with a combination of Enzastaurin and the GSK3 inhibitor AR-A014418 resulted in
upregulation of b-catenin total protein and b-catenin-mediated transcription. Inhibition of b-catenin-mediated
transcription or small hairpin RNA (shRNA) knockdown of b-catenin decreased the cytotoxic effects of
Enzastaurin plus AR-A014418. In addition, treatment with Enzastaurin and AR-A014418 decreased the mRNA
levels and surface expression of CD44. shRNA knockdown of b-catenin also restored CD44 surface expression.
Our observations provide a rationale for the combined targeting of PKC and GSK3 signaling pathways in CTCL
to enhance the therapeutic outcome.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCL) represent a spectrum of
several distinct extranodal non-Hodgkin’s lymphomas. These
lymphomas are characterized by an invasion of the skin by
malignant, clonal CD4þ lymphocytes (Jakob et al., 1996;
Rook et al., 1997). Although treatment may achieve remis-
sion, early chemotherapeutic treatment of CTCL has not
demonstrated survival benefits and no treatments have
proven to be curative. Therefore, new therapeutic approaches
to this disease are needed.
Our laboratory has previously demonstrated that treatment
with the protein kinase C (PKC) b inhibitor Enzastaurin,
which is, to our knowledge, previously unreported, increases
apoptosis in CTCL (Querfeld et al., 2006). These results
directly led to a clinical trial for Enzastaurin in CTCL in which
it was well tolerated and demonstrated modest biological
activity, suggesting that it may serve as a good platform for
combination drug therapies (Querfeld et al., in press). To
improve the efficacy of Enzastaurin, we surveyed comple-
mentary signaling pathways to identify potential synergistic
activity with Enzastaurin. We have identified glycogen
synthase kinase-3 (GSK3) as important in survival signaling
in CTCL. GSK3 is a constitutively active serine/threonine
kinase involved in a wide variety of cellular processes
including glycogen metabolism, transcription, translation,
cell cycle, and apoptosis (Cohen and Goedert, 2004).
One critical downstream target of both PKC and GSK3 is
b-catenin. b-Catenin is a multifunctional protein that has
been implicated in a number of biological processes
including cell–cell adhesion, embryonic development, and
the Wnt signaling pathway. b-Catenin is phosphorylated on
conserved serine and threonine residues, which leads
to its ubiquitination and proteasomal degradation. Inhibition
of b-catenin phosphorylation results in accumulation of
cytoplasmic and nuclear b-catenin and subsequent
binding to transcriptional cofactors such as the TCF/LEF
family of proteins (Gumbiner, 1995; He et al., 1998; Mann
et al., 1999).
A number of genes involved in apoptosis and survival
signaling have been shown to be regulated by b-catenin,
including CD44 (Wielenga et al., 1999; Voutilainen et al.,
2006). CD44 is a transmembrane glycoprotein that has been
shown to deliver survival signals although a number of
intracellular components, including PI3K/Akt, Erk, Ras,
and Lyn (Bates et al., 2001; Lin and Yang-Yen, 2001;
Bourguignon et al., 2005, 2006; Kothapalli et al., 2008).
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In addition, CD44 increases resistance to cellular stress
induced by cytotoxic agents and is able to block p53-
dependent cytostatic and apoptotic signals (Godar et al.,
2008; Xu et al., 2010).
Our data demonstrate the observation that co-treatment
with Enzastaurin and GSK3 inhibitors results in an increase in
apoptosis in part through upregulation of b-catenin levels and
modulation of the transcriptional activity of b-catenin. To our
knowledge, this is previously unreported. This increase in
b-catenin represses expression of the pro-survival factor
CD44 at the mRNA and protein level. Knockdown of
b-catenin restored cell survival as well as expression of
CD44. Combination therapy, which targets both PKC and
GSK3, may offer better clinical options for CTCL.
RESULTS
Previous data from our laboratory indicate that treatment with
Enzastaurin results in an increase in apoptosis in HH and
HuT-78 CTCL cell lines (Querfeld et al., 2006). Because of
the modest efficacy of Enzastaurin in phase II clinical trial in
CTCL, we sought to identify pathways that could enhance the
cytotoxicity of Enzastaurin. Recent in vitro and in vivo studies
have suggested that the GSK3 signaling pathway is important
for survival of malignant cells (Ougolkov et al., 2005, 2007).
To test whether GSK3 is an important survival factor in CTCL,
we treated HuT-78 cells with three structurally distinct GSK3
inhibitors; LiCl, AR-A014418, and SB216763. None of the
GSK3 inhibitors alone significantly affected the rate of
apoptosis. However, when combined individually with
Enzastaurin all three achieved a statistically significant
increase in the rate of apoptosis compared with Enzastaurin
alone (Figure 1a, see Supplementary Figure S1 online). AR-
A014418 was chosen as a GSK3 inhibitor for remaining
experiments due to its high specificity for GSK3 and lack of
off-target effects compared with the other two inhibitors
(Cohen and Goedert, 2004).
The combination of Enzastaurin and AR-A014418 was
also examined in other CTCL-derived cell lines to determine
whether GSK3 inhibition increased the cytotoxicity of
Enzastaurin in a similar manner. Enzastaurin combined with
AR-A014418 increased apoptosis compared with DMSO
control or either drug alone in the cell lines HH, H9, and MJ
(Figure 1b). These results demonstrate that the increase in
apoptosis induced by this combination of drugs is not
restricted to a single cell line.
To determine the therapeutic potential of inhibiting PKC
and GSK3, we extended our studies beyond cell lines to
include ex vivo samples isolated from CTCL patients.
Malignant cells from several CTCL patients were collected,
incubated with the inhibitors, and assessed for percentage of
cells undergoing apoptosis. The program Calcusyn was used
to determine whether the combination of Enzastaurin and
AR-A014418 exhibited synergy (http://www.biosoft.com/w/
calcusyn.htm). Cells were treated with the inhibitors and the
combination index was calculated. A combination index of
less than one is interpreted as synergy between the two
compounds, whereas a combination index equal to one
suggests additivity. Treatment with the combination of
Enzastaurin and AR-A014418 increased apoptosis in a
synergistic or additive manner in all patient samples,
suggesting that this drug combination holds potential in
treating CTCL (Table 1).
Both PKC and GSK3 can phosphorylate b-catenin and
target it for subsequent proteasomal degradation (Chen et al.,
2000; Gwak et al., 2006; Raab et al., 2009). Inhibition of
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Figure 1. Glycogen synthase kinase-3 inhibitors combined with Enzastaurin
increase apoptosis. (a) HuT-78 cells were cultured in 4 mM Enzastaurin, 5mM
LiCl, 5 mM AR-A014418, 5 mM SB216763, or DMSO (vehicle control) and
collected after 5 days. (b) HH, H9, and MJ cells were cultured in 4mM
Enzastaurin (H9), 8 mM Enzastaurin (HH, MJ), 5 mM AR-A014418 (H9), 10 mM
AR-A014418 (MJ), 20 mM AR-A014418 (HH), or DMSO (vehicle control) and
collected after 5 days. Detection of Annexin V and 40-6-diamidino-2-
phenylindole (DAPI) staining for all cells was performed as described
previously. Data from three separate experiments were averaged to quantify
apoptotic cells (double positive cells) as a percentage of total cells. Error bars
represent standard deviation.
Table 1. CI values at different concentrations of
Enzastaurin and AR-A014418 in ex vivo patient
samples
Patient Enzastaurin (lM) ARA014418 (lM) CI
P1 2 5 0.805
4 5 0.784
P2 2 5 0.737
4 5 0.825
P3 2 5 0.872
4 5 0.936
P4 2 5 0.563
4 5 0.954
P5 2 5 0.568
4 5 0.801
Abbreviation: CI, combination index.
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b-catenin phosphorylation can lead to increased transcrip-
tional activity of b-catenin and modulation of gene expres-
sion, including a number of genes involved in apoptosis and
survival signaling (Clevers and van de Wetering, 1997; He
et al., 1998; Mann et al., 1999). To determine whether PKC
and GSK3 regulate b-catenin levels in CTCL, we cultured
cells in the presence of Enzastaurin and AR-A014418.
Treatment with Enzastaurin alone or Enzastaurin and
AR-A014418 resulted in an upregulation of b-catenin protein
levels (Figure 2). We also used an antibody that detects
unphosphorylated b-catenin to determine whether the
phosphorylation state of b-catenin was affected by the
inhibitors. Treatment with the combination of Enzastaurin
and AR-A014418 decreased phosphorylation of b catenin
compared with Enzastaurin alone.
Unphosphorylated b-catenin is targeted to the nucleus to
form a nuclear complex with TCF/LEF transcription factors
(Huber et al., 1996; Eastman and Grosschedl, 1999). To
determine whether the combination of inhibitors increased
the nuclear localization and transcriptional activity of
b-catenin, cells were incubated with the two inhibitors and
cells were fractionated to separate nuclear and cytoplasmic
fractions. a-Tubulin was used as a cytoplasmic marker and
hnRNP A0 was used as a nuclear marker. Treatment with
Enzastaurin and AR-A014418 resulted in an increase of
nuclear b-catenin compared with DMSO control or either
inhibitor alone (Figure 3a). To examine whether inhibitor
treatment affected b-catenin-mediated transcription, we used
a TCF/b-catenin luciferase reporter. Cells were transfected
with the reporter and treated with the inhibitors Enzastaurin
and AR-A014418. Neither Enzastaurin nor AR-A014418
alone significantly increased luciferase activity (Figure 3b).
However, the combination of both inhibitors resulted in an
increase in luciferase activity. Cells were also transiently
transfected with ICAT, a protein which represses TCF/b-
catenin-mediated transactivation by inhibition of the inter-
action between b-catenin and TCF (Tago et al., 2000). ICAT
expression decreased luciferase activity compared with
vector control in cells treated with Enzastaurin and
AR-A014418. In a separate experiment, cells were transiently
transfected with a control luciferase reporter, FOPGLOW
(mutant TCF binding sites) and no significant difference in
activity was observed between cells treated with DMSO
control or any of the inhibitors (Figure 3c).
To determine whether b-catenin-mediated gene regulation
is important in modulating cell survival, we transiently
transfected HuT-78 cells with either the ICAT vector or an
empty vector control, treated with the inhibitors and
examined the percentage of cells undergoing apoptosis. In
cells co-treated with Enzastaurin and AR-A014418, ICAT
expression decreased apoptosis compared with vector con-
trol (Figure 4a). This suggests that b-catenin-mediated gene
regulation is in part responsible for the activation of apoptosis
in cells treated with Enzastaurin and AR-A014418. To
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Figure 2. Enzastaurin combined with AR-A014418 increases
unphosphorylated (active) b-catenin levels. HuT-78 cells were cultured in
standard drug conditions of DMSO, 4 mM Enzastaurin, 5 mM AR-A014418, or
the combination of Enzastaurin and AR-A014418 and lysates were prepared
at 24 hours. Immunoblots were performed as described previously. Blot is
representative of three separate experiments. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
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Figure 3. Enzastaurin combined with AR-A014418 increases nuclear
localization and transcriptional activity of b-catenin. (a) HuT-78 cells were
cultured in the standard drug conditions of DMSO, Enzastaurin, or AR-
A014418 and collected at 24 hours. Cells were fractionated and resultant
lysates were immunoblotted with indicated antibodies. (b) HuT-78 cells
were transfected with 3 mg TOPGLOW luciferase reporter (Millipore,
Billerica, MA) and either PC3DNA or ICAT vector, treated with inhibitors, and
collected after 24 hours. (c) HuT-78 cells were transfected with 3 mg
FOPGLOW luciferase reporter (Millipore) and either PC3DNA or ICAT vector,
treated with inhibitors, and collected after 24 hours. Luciferase reporter assays
were carried out using manufacturer’s instructions (Promega).
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confirm these results, we knocked down b-catenin using a
small hairpin RNA (shRNA)-expressing lentivirus. Cells were
transduced with either control lentivirus or b-catenin shRNA
lentivirus and selected in puromycin. Cells were then treated
with Enzastaurin and AR-A014418 and b-catenin protein was
examined by immunoblot. Total b-catenin levels were
decreased in cells transduced with the b-catenin shRNA
lentivirus compared with cells transduced with control
lentivirus (Figure 4b). Apoptosis was also measured in the
b-catenin knockdown and control cells. A decrease in the
percentage of cells undergoing apoptosis when treated with
Enzastaurin and AR-A014418 was observed in the b-catenin
knockdown cells compared with control cells (Figure 4c,
see Supplementary Figures S2 and S3 online). Similarly,
b-catenin levels were also knocked down in the CTCL cell
lines HH, H9, and MJ. Knockdown of b-catenin levels in all
three cell lines resulted in a decrease in the percentage of
cells undergoing apoptosis when treated with Enzastaurin
and AR-A014418 compared with control cells (Supplemen-
tary Figures S2 and S3 online).
b-Catenin can modulate the transcription of several genes
involved in survival signaling, including CD44. We exam-
ined mRNA levels of CD44 in cells treated with Enzastaurin
and AR-A014418 to determine whether the increase in
b-catenin levels resulted in a decrease in gene expression.
Treatment with Enzastaurin or the combination of Enzastaurin
and AR-A014418 resulted in a decrease in CD44 mRNA
levels (Figure 5a). To determine whether treatment with the
inhibitors nonspecifically decreases all transcriptional targets
of b-catenin, we examined the effect of Enzastaurin and AR-
A014418 on c-Myc and cyclin D1. Treatment with the two
inhibitors did not significantly affect expression of c-Myc or
cyclin D1 (data not shown), suggesting that co-treatment with
Enzastaurin and AR-A014418 modulates only a subset of
b-catenin responsive genes.
To determine whether this decrease in CD44 mRNA
resulted in lower surface expression of CD44, cells were
treated with the two inhibitors and examined by flow
cytometry. Surface expression of CD44 decreased in cells
treated with the two inhibitors compared with cells treated
with either inhibitor alone or DMSO control (Figure 5b). To
confirm that the observed decrease in CD44 surface
expression was mediated by b-catenin, b-catenin was
knocked down and cells were treated with the two inhibitors.
Knockdown of b-catenin resulted in a restoration of surface
CD44 levels, suggesting that b-catenin was indeed respon-
sible for the drug-induced decrease in CD44 (Figure 5c).
DISCUSSION
The goal of cancer therapeutics is to eliminate cancer cells
with minimal damage to nonmalignant cells. The combina-
tion of Enzastaurin and AR-A014418 seeks to achieve this
goal by inhibiting complementary survival pathways impor-
tant for tumor cell survival and allows for lower doses of the
individual drugs that may be less toxic to nonmalignant cells.
Treatment with Enzastaurin and AR-A014418 results in
enhanced apoptosis in CTCL cell lines as well as in patient
samples, suggesting that GSK3 and PKC signaling pathways
have important roles in CTCL. Treatment with Enzastaurin
and AR-A014418 resulted in a decrease in b-catenin
phosphorylation, an accumulation of cytoplasmic and
nuclear b-catenin and an increase in transcriptional activity.
This increase in transcriptionally active b-catenin resulted in
an increased rate of apoptosis and transcriptional changes in
CD44. Together, this points to the combination of PKC and
GSK3 inhibition as a potential treatment for CTCL.
Although Enzastaurin primarily affects PKC, Enzastaurin
has been shown to inhibit other AGC (cAMP-dependent
protein kinase/protein kinase G/protein kinase C) family
kinases involved in survival signaling, including Akt and
p90RSK (Graff et al., 2005). We have not ruled out the
possibility that the Enzastaurin-mediated increase in apopto-
sis observed in CTCL may be due in part to additional factors
outside of the inhibition of PKC. Additional studies will be
needed to better define the critical targets of Enzastaurin.
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Figure 4. b-Catenin-mediated transcription increases apoptosis in cutaneous
T-cell lymphomas. (a) HuT-78 cells were transfected with 3 mg green
fluorescent protein expressing vector and either PC3DNA or ICAT vector.
Detection of Annexin V and 40-6-diamidino-2-phenylindole (DAPI) staining
was performed as described previously. Data from three separate experiments
were used to quantify double positive cells as a percentage of total cells. Error
bars represent standard deviation. (b) b-Catenin expression was knocked
down in HuT-78 cells using a small hairpin RNA (shRNA)-expressing
lentivirus. Cells were then treated with inhibitors and b-catenin protein was
examined by immunoblot after 24 hours. (c) Detection of Annexin V and
DAPI staining was performed on HuT-78 cells transduced with lentivirus as
described previously. Data from three separate experiments were used to
quantify double positive cells as a percentage of total cells. Error bars
represent standard deviation. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
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b-Catenin has been shown to be overexpressed in some
CTCL patients (Bellei et al., 2004, 2006). b-Catenin accumu-
lation was seen in 31% of the mycosis fungoides samples and
70% of the Se´zary syndrome samples in one study and 46%
of mycosis fungoides cases in another study (Bellei et al.,
2004, 2006). However, the b-catenin observed in these tumor
samples was not found in the nucleus and there was no
detectable expression of b-catenin/TCF target genes (Bellei
et al., 2004). This suggests that the mere presence of b-
catenin will not necessarily trigger apoptosis in CTCL.
Translocation to the nucleus and transcriptional activity appear
to be important in activating apoptosis. It is also likely that the
specific cofactors that bind to b-catenin also have a role. In
addition to members of the TCF/LEF family of transcription
factors, b-catenin can associate with a number of other
cofactors to modulate transcription, including p300, CBP,
histone deacetylases, and FOXO family proteins (Billin et al.,
2000; Hecht et al., 2000; Takemaru and Moon, 2000;
Hoogeboom et al., 2008). The expression of ICAT may disrupt
the interaction of b-catenin with other proteins besides TCF/LEF
family members, such as p300 (Daniels and Weis, 2002).
b-Catenin has been shown to not only upregulate
expression of TCF/b-catenin target genes but also repress
gene expression (Deng et al., 2002, 2004). For example,
b-catenin has been shown previously to inhibit transcription
factors involved in survival signaling, such as NF-kB (Deng
et al., 2002, 2004). Although some studies have suggested
that b-catenin may positively regulate the expression of
CD44, b-catenin appears to repress the expression of CD44 in
the context of Enzastaurin and AR-A014418 treatment in
CTCL cells.
Although Enzastaurin alone was able to decrease mRNA
levels of CD44, only the combination of Enzastaurin and AR-
A014418 was able to decrease surface expression of CD44.
The control of CD44 expression is very complex and likely
influenced by a number of factors, including splicing and
posttranslational regulation. Expression of specific isoforms of
CD44 can be regulated by PI3K and PKC (Fichter et al.,
1997). b-Catenin can not only affect CD44 mRNA expres-
sion, but has also been shown to modulate splicing of CD44
isoforms (Goncalves et al., 2008). We used primer probe sets
and flow cytometry antibodies that could detect all splice
variants and isoforms of CD44, respectively. Treatment with
Enzastaurin and AR-A014418 may only be inhibiting the
surface expression of a subset of all CD44 isoforms. Further
experiments will need to be conducted to determine the
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Figure 5. Enzastaurin combined with AR-A014418 modulates expression of CD44. (a) RNA was isolated from HuT-78 cells treated with inhibitors and
data from three separate experiments were used to calculate the change in gene expression as a percentage of DMSO control. Error bars represent standard
deviation. (b) HuT-78 cells were stained with antibodies that detect CD44 and examined by flow cytometry. Cells in late apoptosis bind antibodies
nonspecifically and were therefore gated out during analysis. Error bars represent standard deviation from three separate experiments. (c) HuT-78 cells
transduced with lentiviruses were stained with antibodies against CD44 and examined by flow cytometry. Error bars represent standard deviation from
three separate experiments.
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specific isoforms of CD44 affected by the combination of
Enzastaurin and AR-A014418.
All different subtypes and stages of CTCL have been shown
to express CD44 (Orteu et al., 1997). In addition, CD44
functions in PKC-regulated migration of T cells (Fanning
et al., 2005). Inhibition of PKC by Enzastaurin as well as the
induced decrease of CD44 may be a particularly effective
therapeutic against the skin-homing malignant lymphocytes
of CTCL.
The concentrations of both Enzastaurin and AR-A014418
used in these experiments have been previously shown to be at
or below achievable levels in vivo. Phase I clinical trials
showed that steady-state plasma concentrations of up to 8mM
Enzastaurin are achievable in patients (Graff et al., 2005).
Although no pharmacokinetic data for AR-A014418 exists for
humans, blood plasma concentrations of 3.75mM AR-A014418
have been measured with oral dosing of 1mmol kg1 in
Sprague–Dawley rats and much higher dosages (10-fold) been
used with no reported dose-limiting toxicities (Martins et al.,
2011; Medina and Avila, 2010; Gould et al., 2004).
The combination of Enzastaurin and AR-A014418 has the
potential to affect a number of important signaling pathways.
In vivo experiments in mice will be needed to address if the
combination of Enzastaurin with a GSK3 inhibitor activates
synergistic toxicities or if it has other off-target effects. For
example, Enzastaurin is able to inhibit both natural and
antibody-dependent cellular cytotoxicity of natural killer (NK)
cells against tumor targets, and therefore may suppress NK cell-
mediated activity against tumor cells (Ogbomo et al., 2011).
Interestingly, treatment of NK cells with a GSK3 inhibitor
reversed Enzastaurin-mediated inhibition of NK cell cytotoxi-
city. In vivo experiments will be needed to address these and
other potential positive and negative off-target effects.
Understanding the role of PKC and GSK3 in survival
signaling in CTCL will provide insight into the biology of
CTCL as well as define rational targets for therapy. Our
observations point to the importance of targeting these two
pathways in CTCL and the possibility of an improvement in
therapeutic outcome.
MATERIALS AND METHODS
Cell lines and cell culture
HH, H9, HuT-78, and MJ cells were grown in RPMI 1640 (Invitrogen,
Baltimore, MD) supplemented with 10% fetal bovine serum (MJ in
20%), 2mM glutamine, 100Uml1 penicillin, 100mgml1 strepto-
mycin, and 2.5mgml1 amphotericin B. For primary samples,
Northwestern University IRB approval was obtained for this study,
and each patient provided written, informed consent. The study
complied with the Declaration of Helsinki protocols. Blood samples
were collected from CTCL patients and peripheral blood mononuclear
cells (PBMCs) were isolated using BD Vacutainer CPT tubes (BD
Biosciences, San Jose, CA). CD4 positive cells were then isolated
using manufacturer’s instructions for the EasySep immuno-magnetic
cell separation kit (StemCell Technologies, Vancouver, BC, Canada).
Antibodies and reagents
ICAT vector was a gift from the Gottardi Laboratory. Antibodies
against b-catenin and active b-catenin were purchased from
Millipore (Temecula, CA). Antibodies against a-tubulin and hnRNP
A0 were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). CD44 antibodies were purchased from BD Biosciences. All
other antibodies were purchased from Cell Signaling. Enzastaurin
was a gift from Eli Lilly (Indianapolis, IN). Annexin 40-6-diamidino-2-
phenylindole staining was performed according to the manufac-
turer’s instructions (BD Pharmingen, San Diego, CA). Flow
cytometry data were recorded by using a DakoCytomation CyAn
machine, and samples analyzed by using FCS Express.
Cell viability assay
Cell viability assays were carried out using 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
reagent from Promega according to the manufacturer’s instructions
(Madison, WI). The data are expressed as percentage of DMSO
control cells.
Transfection
HH and HuT-78 cells were transiently transfected using an Amaxa
Nucleofector I device (Lonza, Cologne, Germany). Five million HuT-
78 cells were electroporated in 0.1ml of Solution V using the T-01
program with 3mg of the appropriate vector.
Luciferase assay
Cells were transiently transfected with 3mg of plasmid vector and
incubated at 37 1C for 24 hours. Lysates were prepared 24 hours
post-transfection using the Promega Luciferase Assay System
according to the manufacturer’s instructions (Promega). Lumines-
cence was measured for 15 seconds using a BioTek Synergy HT plate
reader (BioTek, Winooski, VT). Luminescence was normalized to
protein concentration of sample.
Cell fractionation
Cells were washed twice in phosphate-buffered saline and resus-
pended in 1ml buffer A (10mM HEPES, pH 7.5, 10mM KCl, 1mM
EDTA, 1mM dithiothreitol (DTT), 1mM MgCl2, 5% v/v glycerol,
0.1mM Na3VO4) for 10min on ice. A volume of 25 ml buffer B
(10mM HEPES, pH 7.5, 10mM KCl, 1mM EDTA, 1mM DTT, 1mM
MgCl2, 5% v/v glycerol, 0.1mM Na3VO4, 10% v/v Nonidet P-40)
was added and lysates were spun down at 4,000 r.p.m. for
10minutes at 4 1C. Supernatant was collected (cytoplasmic fraction)
and stored. Remaining pellet was washed twice with 1ml buffer C
(10mM HEPES, pH 7.5, 10mM KCl, 1mM DTT, 1mM MgCl2) and
resuspended in 500 ml of buffer D (20mM HEPES, pH 7.5, 0.4M
NaCl, 1mM EDTA, 1mM DTT, 1mM MgCl2, 25% v/v glycerol).
Lysates were incubated for 15minutes on ice with intermittent
vortexing and then spun down at 15,000 g for 5min at 4 1C.
Supernatants were collected (nuclear fraction) and stored.
Reverse transcription PCR
RNA lysates were prepared using RNeasy Kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. Reverse transcriptase
step was run on Eppendorf Master Cycle Thermocycler (Eppendorf,
Hauppauge, NY). Real-time PCR was performed using the TaqMan
Gene Expression Assay (Applied Biosystems, Foster City, CA) and run
on 7500 Fast Real Time PCR Machine (Applied Biosystems). Samples
were run in triplicate. Reverse transcription PCR was performed a
minimum of three independent times for each gene. RNA expression
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was normalized to three independent control genes using geNorm
(http://medgen.ugent.be/~jvdesomp/genorm/).
Immunoblotting and immunoprecipitation
Lysates were prepared and resuspended in SDS loading buffer,
heated to 95 1C for 5min, separated by 10% SDS-PAGE and
transferred to Immobilon membranes. Membranes were blocked in
BLOK Casein in TBS (G Biosciences, St Louis, MO) for 1 hour at
room temperature, incubated overnight in BLOK containing the
appropriate primary antibodies at 4 1C, washed three times in Tris-
buffered saline with Tween, and incubated with secondary
antibodies in BLOK for 1 hour at room temperature. For detection,
membranes were washed three times in tris buffered saline with
tween and detected with ECL Plus (Pierce, Rockford, IL).
Lentivirus production and transduction
Lentiviruses were produced using the Lentiphos HT kit (Clontech,
Mountain View, CA) and GIPZ Lentiviral shRNAmir constructs
according to the manufacturer’s instructions (Open Biosystems,
Huntsville, AL). To transduce the cells, one million cells were plated
per well in a 6-well plate with 5ml of viral supernatant and 5 ml of
polybrene. Cells were spun for 2 hours at 3,200 r.p.m. at room
temperature.
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